National Institute of Allergy and Infectious Diseases

The NIH's National Institute of Allergy and Infectious Disease (NIAID) is charged with overseeing research on HIV and HCV. The NIAID's Director, Anthony Fauci, MD, is America's chief HIV/AIDS researcher who received an NIAID grant totaling $183,959 from his Institute's paltry $34 million HCV budget. HepCop contends Fauci should have funded his research from his Institute's $1.3 billion HIV budget. The primary beneficiaries of Fauci's funding are not the many millions of patients solely infected with HCV, but rather only a few hundred thousand HIV patients who also have HCV.

HepCop is concerned that a possible conflict-of-interest exists and points out that any suggested justification for redirection of HCV funds to additional HIV/AIDS research seems to be inconsistent with Fauci's own statement on CNN: "...the scientific advancements that have been made in HIV (research) are breathtaking (with) highly effective drugs to suppress HIV to the point where what was a death sentence in the early eighties to now having patients who look and feel well, who are leading very productive, very gratifying lives..."

The inescapable reality is that the HIV research has been so heavily funded that it reached its successful goal of developing life-saving drugs years ago. For example, the rate of AIDS deaths in California's newly infected patients has fallen 98 percent since 1992 from 9,797 deaths to 157 deaths in 2007 (as of 3/31/09).

---

Total NIAID HCV Research Funding
$33,936,386
 

	Description	Project Number	Researcher	Cost	Project Title
$2,050,429	HBV/Viral Hep Study	1Z01AI001015-02	PTACEK, JENNIFER	$684,996	Pathogenesis of Parenteral Viral Hepatitis
		5R01AI071068-03	KHALILI, MANDANA	$377,376	RNAi for the Treatment of Viral Hepatitis
		1Z01AI000915-07	PTACEK, JENNIFER	$988,057	Pathogenesis Of Enteric Viral Hepatitis
		5R43AI072842-02	UPRICHARD, SUSAN	$299,978	Liquid Crystal Diagnostic for Multiplex Hepatitis Screening
$19,400,468	HCV Based Study	5R01AI067926-03	ALLEN, TODD	$169,784	CD8 T Cell Selective Pressure and HCV Sequence Evolution
		5R21AI072180-02	DASH, SRIKANTA	$188,843	Towards Developing type 1a HCV cell culture model
		5R03AI069090-02	OPELLA, STANLEY	$95,648	Role of mitochondrial core protein in Hepatitis C Virus pathogenesis
		2R01AI060389-07	GHANY, MARC	$383,372	The Host Response to Hepatitis C Virus
		1R01AI075099-01A1	REDDY, RAJENDER	$420,000	Role of HCV p7 and NS2 in infectious virus production
		1R21AI065535-01A2	RANGSIN, RAM	$183,135	Developing an in vitro system for HCV propagation
		1K08AI075031-01A1	CHARLES, EDGAR	$140,400	The Pathogenesis of Autoimmunity in Hepatitis C Virus Infection
		5R01AI070101-03	GRETCH, DAVID	$401,835	Mechanisms of hepatitis C virus persistence
		1R41AI072859-01A2	BLYN, LAWRENCE	$290,535	HCV Genotyping and Drug Resistance Testing by ESI/MS
		1K99AI077800-01	EVERSON, GREGORY	$90,000	Studies of hepatitis C virus polarized cell entry and host factor requirements
		5R21AI070769-02	LUO, GUANGXIANG	$215,575	Hepatitis C virus infection and lipoproteins
		5R01AI047519-10	CHANG, KYONG-MI	$304,162	Cellular immunity - outcome hepatitis C virus infection
		5R01AI070827-03	SU, LISHAN	$231,928	High Throughput in vitro Hepatitis C Virus Screening
		5R01AI068966-03	KAY, MARK	$233,034	Cellular Immune Responses in Subjects Exposed to Hepatitis C
		5R01AI047365-09	RAY, RANJIT	$362,764	Structure and Function of the Hepatitis C Virus Genome
		5U01AI070834-04	ECKELS, DAVID	$354,663	Development of Listeria-Based Clinical Consensus HCV Vaccine Candidates
		5U01AI070802-03	NICOSIA, ALFREDO	$180,033	Development of an Adenovirus based HCV Vaccine: preclinical safety and immunology
		5F32AI069693-02	DELGADO, AYMIN	$49,646	Novel role of NS2 in HCV infection
		1R01AI079031-01	LEMON, STANLEY	$473,750	Discovery of potent human antibodies for prevention of (recurrent) HCV infection
		5R43AI072785-02	TIEN, PHYLLIS	$300,000	Development of a Proplylactic HCV Vaccine
		1R01AI073335-01A2	KAZAKOV, SERGEI	$287,713	RNA-dependent RNA Synthesis by the Hepatitis C Virus
		5R01AI057591-04	HASSAN, MANAL	$282,356	Alteration of innate immunity by HCV core
		5R37AI047367-09	TAI, ANDREW	$541,702	HCV-specific T cell response
		5R01AI072613-02	REDDY, RAJENDER	$414,473	Identification and characterization of cellular factors involved in HCV entry
		5R01AI065985-03	BLIGHT, KERIL	$289,575	Defining NS4B Function in Hepatitis C Virus Replication
		5R01AI061158-04	NELSON, DAVID	$304,514	Mechanisms of Innate and Adaptive Immunity In HCV
		5R01AI069000-03	RAY, RANJIT	$295,433	Roles for microRNA-122 in hepatitis C virus RNA amplification
		5R01AI069142-02	SHIFFMAN, MITCHELL	$333,295	Immune Mechanisms of HCV Persistence and Pathogenesis
		1R21AI076706-01	ALTFELD, MARCUS	$263,250	Impact of NK Cell Immune Pressures on HCV Evolution and Viral Fitness
		1R21AI076834-01	DIENSTAG, JULES	$183,750	Cell Culture System for Hepatitis C Virus Genotype 1a
		5R01AI061684-05	BHARDWAJ, NINA	$571,176	Dendritic Cell mediated induction of Anti-HCV immunity
		5R01AI069952-03	BACCHETTI, PETER	$178,477	Statistical methods for modeling hepatitis C fibrosis progression
		1R21AI079352-01	DUBENSKY, THOMAS	$249,000	Eliciting neutralizing antibodies against the HCV E2 envelope glycoprotein
		5R01AI047347-10	EDLIN, BRIAN	$455,271	Regulation of human T-cell immunity to HCV antigens
		5R01AI066209-03	HARRISON-FINDIK, DUYGU DEE	$408,680	Viral Host Interactions in Hepatitis C
		5R01AI050798-05	MCKEATING, JANE	$200,490	Functional analysis of hepatitis C virus glycoproteins
		5R01AI072012-02	HINKIN, CHARLES	$367,061	New Antiviral Therapies for Hepatitis C Infection
		5R43AI072780-02	O'BRIEN, THOMAS	$287,309	Broadly Neutralizing MAbs against Hepatitis C Virus
		5R01AI068769-03	RANGSIN, RAM	$315,056	QUALITATIVE NATURE OF ANTIBODIES TO HCV GLYCOPROTEIN SUBUNIT VACCINE IN HUMANS
		5R01AI049574-08	LAUER, GEORG	$311,605	GBV-B: A Small Primate Model for Hepatitis C Infection
		5R03AI067440-03	MOHAMED, MOSTAFA	$43,078	Feasibility for non-Invasive screening for HCV related fibrosis
		5K08AI072191-02	PURCELL, ROBERT	$128,250	Mechanisms of T cell dysfunction in Hepatitis C virus persistence
		5R01AI069285-02	LIANG, T. JAKE	$126,887	Role of TLR3 Signaling in Control of HCV
		5U19AI066345-04	SZABO, GYONGYI	$129,397	Dynamics of CD4 Responses in Acute Hepatitis C Virus Infection
		2R56AI060563-05A2	RAISON, CHARLES	$396,583	HCV NS3 and NS5A: Biochemical Mechanisms and Biological Functions
		5U19AI048231-09	TAI, ANDREW	$436,583	HCV-Specific Cellular Immunity in Acute Hepatitis C
		1K08AI079406-01	EKSIOGLU, ERIKA	$130,599	Novel antviral targets in Hepatitis C virus NS4B protein
		5U19AI048231-09	KIM, ARTHUR	$234,281	Natural Killer Cell Receptors and Hepatitis C
		5U19AI066316-04	MARION, TONY	$222,521	HLA -Dependent Racial Differences in Immune Response in Chronic Hepatitis C Virus
		5U19AI066316-04	PERLMAN, DAVID	$227,085	Interferon System Underlie Differential Response to Therapy for Hepatitis C Virus
		5U19AI066328-04	RITOLA, KIMBERLY	$143,390	Innate and Regulatory Immune Responses in Acute HCV
		5U19AI066328-04	PILLAI, SATISH	$243,476	HCV-Host Interaction during Acute Hepatitis C
		5U19AI066328-04	HASSAN, MANAL	$216,575	Suppression of HCV-specific CD4+ T Cell Function by Core Protein
		5U19AI040035-13	GHANY, MARC	$208,529	Innate Defenses that Control Hepatitis C Virus (HCV)
		5U19AI066345-04	KOVACS, ANDREA	$127,822	Acute Hepatitis C Virus Infection in the Prison Population
		5U19AI048231-09	KATZE, MICHAEL	$247,325	Molecular Analysis of HCV-specific T Cell Responses
		5U19AI066345-04	LEE, JOSHUA	$252,359	The Role of CD8+ T-cell Responses In Acute Hepatitis C Virus Infection
		5U19AI066345-04	ALLEN, TODD	$252,306	CD8 T Cell Seletive Pressure and Hepatitis C Virus Sequence Evolution
		7R01AI069285-03	LIANG, T. JAKE	$128,837	Role of TLR3 Signaling in Control of HCV
		1R56AI079043-01	CHISARI, FRANCIS	$473,750	Innate Control of Hepatitis C Virus Infection: Antiviral and Evasion Mechanisms
		5U19AI066332-04	MASON, HUGH	$286,659	Plant-Derived Envelope gpE1/E2 Vaccine for HCV
		5U19AI066332-04	ARNTZEN, CHARLES	$272,474	Plant-Based Production of Non-Envelope Antigens of HCV
		3U19AI066345-03S1	LEE, JOSHUA	$12,261	Supplemental Funds to Acquire HCV Volunteers
		5U54RR019507-06	MAYOR, ANGEL	$15,062	HCV RISK REDUCTION INTERVENTION AS SECONDARY CO-MORBIDITY PREVNT
		1Z01AI000970-03	EMOND, JEAN	$384,800	Molecular Studies of Hepatitis C Virus.
		5U19AI066345-04	RADZIEWICZ, HENRY	$167,689	Identification of acute Hepatitis C Virus infection in Rio de Janerio
		1F32AI080093-01	POLYAK, STEPHEN	$44,846	Reconstitution of Poliovirus and HCV RNA Replication Complexes on Membranes
		5U19AI040034-14	REDDY, RAJENDER	$263,201	HCV Infection Systems and Role of Neutralizing Antibodies in Hepatitis C
		5U19AI066313-04	REDDY, RAJENDER	$110,208	Viral, T Cell, and Cytokine Determinants of Hepatic Stellate Cell Activation
		5U19AI066313-04	RUSSELL, MARCIA	$160,781	Hepatitis C Virus- Induced Steatosis
		1F32AI080122-01	SMITH, MICHAEL	$56,702	Whole-genome siRNA screen for host genes supporting hepatitis C virus replication
		1R01AI075090-01A2	WHITACRE, DAVID	$302,000	Function of NS2 in Hepatitis C Virus Assembly and Release
		1R01AI073963-01A1	BLANTON, RONALD	$500,000	Host Genetic Contribution to HCV Outcomes
		5U19AI040035-13	LAUER, GEORG	$221,341	Virus-Host Interactions in Hepatitis C Virus (HCV) Infections
		5U19AI040035-13	RAY, RANJIT	$189,867	Cellular Immune Failure in Acute Hepatitis C
		5U19AI040035-13	LI, KUI	$133,673	Interferon Signaling and Cellular Permissiveness for Hepatitis C Virus (HCV)
$1,030,509	HIV Based Study	N01AI25488-0-0-1	NO PI IDENTIFIED	$1,030,509	Drug Dev for Opportunistic Inf. - Cell and Animal Model Development for Hep. C
$2,297,498	HIV/HCV Mental Health Study	5R01AI069939-03	CHUNG, RAYMOND	$375,067	HIV-Hepatitis C Virus Interactions and Pathogenesis
		5K23AI066943-04	STERN, STEPHEN	$121,770	Gender Effects of HIV and HCV on lipodystrophy, glucose disorders, and steatosis
		5R21AI066957-02	ANTHONY, DONALD	$189,456	Immunity of neoantigen response in HCV, HIV, and HCV-HIV
		5K23AI065319-04	MARKS, KRISTEN	$131,490	Thrombocytopenia & HIV/HCV: Risk Factors & Treatment
		1Z01AI000733-14	BERGER, EDWARD	$294,681	Enveloped Virus Glycoprotein/receptor Interactions
		5K01AI070001-02	LOFFREDO, CHRISTOPHER	$133,029	Risk factors and prediction of liver disease in HIV/HCV
		5R43AI074255-02	KIEFT, JEFFREY	$299,965	Multiplexed mRNA quanitification using self-circularizing RNA probes
		5R01AI049168-08	HARRISON-FINDIK, DUYGU DEE	$568,445	HCV Replication and Immune Response in HIV Coinfection
		1Z01AI000390-25	FISHER, ROBERT	$183,595	Therapeutic Strategies for the Management of HCV/HIV co- infection
$1,605,509	Interferon/Antivial Treatment HCV Study	1R43AI078638-01A1	MORCOL, TULIN	$142,250	Calcium phosphate-interferon (CaP-IFN) particles for pulmonary delivery of IFN
		5R01AI065256-03	RODRIGUES, LIA	$686,648	Antiretroviral Therapy and the Hepatitis C Virus
		5K08AI069989-02	WANG, XIN	$105,570	An in vitro system to study antiviral strategies against Hepatitis C virus
		5U19AI040034-14	HAHN, YOUNG	$219,246	Global Transcriptional Responses in IFN Therapy for HCV
		5K23AI065630-04	JOHNSON, RAY	$124,200	Molecular Basis of Interferon Response in HCV
		1F31AI071353-01A2	EL-BASSEL, NABILA	$31,852	Type I Interferon Responses to Hepatitis C Virus
		1R43AI074214-01A1	KAMAL, SANAA	$295,743	An RNAi Trojan Horse for treatment of hepatitis C.
$3,153,024	Interferon/Antivial Treatment HIV/HCV Study	2R01AI052065-05A2	KULIG, CLARK	$533,057	HCV and HIV Progression in Women on HAART
		1Z01AI001016-02	PTACEK, JENNIFER	$690,432	New Approaches To Passive Immunoprophylaxis
		1Z01AI000823-11	PTACEK, JENNIFER	$836,285	New Approaches To Active Immunoprophylaxis
		5R37AI028731-19	LITWIN, ALAIN	$324,651	Noncarbohydrate Approaches to AntiAIDS Nuleosides
		1R01AI073219-01A2	MONTANER, LUIS	$632,784	NK/DC Cross-Talk and Antiviral Response
		5K01AI073193-02	LINDBLAD, ANNE	$135,815	Improving HIV and HCV outcomes in U.S. AIDS Drug Assistance Programs
$890,202	Liver Disease Study	1Z01AI000999-02	FISHBEIN, DAWN	$603,252	Molecular Mechanisms of Pathogenesis of Acute and Chronic Liver Diseases
		5U19AI066313-04	LAI, MICHAEL	$154,065	Immunologic Correlates of Liver Disease Progression
		5R43AI072802-02	FRICK, DAVID	$132,885	Identification of an inhibitor of microRNA-122 in liver
$2,833,225	Other Treatment Study	5U01AI063589-05	RITOLA, KIMBERLY	$2,244,524	Molecular profiling and immunomodulatory interventions
		5R21AI077018-02	SMITH, RICHARD	$288,701	The novel chromatin-based mechanism of antiviral resistance
		1R43AI075829-01A1	EL-SERAG, HASHEM	$300,000	Generation of novel HCV drugs through engineereing of the cssA gene
$675,522	Unknown	5U19AI040035-13	STERLING, RICHARD	$195,546	Clinical Core
		5U19AI040034-14	WALKER, BRUCE	$191,548	Translational Core
		5U19AI066313-04	AFDHAL, NEZAM	$133,049	Clinical Core
		5U19AI066332-04	LANFORD, ROBERT	$155,379	Administrative Core
		Total NIAID NIH Funding		$33,936,386

---

Source: National Institutes of Health Research Portfolio Online Reporting Tool (RePORT) Reports,
Data and Analyses of NIH Research Activities
Retrieved on March 18, 2009
http://report.nih.gov/rcdc/categories/ProjectSearch.aspx?FY=2008&DCat=Hepatitis+-+C

Permission is granted to use all information from this website in pursuit of ending NIH's "Trans-Plan" discriminatory practices against HCV research funding allocations. Please Credit: HCVets.com Educational Website & Support Forums for Military Related HCV Exposures.

Contact HepCop   
Email: Staff